Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: Incidence and relevance

European Journal of Haematology

Volumn 95, Issue 1, 2015, Pages 83-89

  Adams, Hugo J A ^a   Kwee, Thomas C ^a   Fijnheer, Rob ^b   Dubois, Stefan V ^b   Nievelstein, Rutger A J ^a   de Klerk, John M H ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Biopsy; Bone marrow; Diffuse; FDG PET; Lymphoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CANCER INCIDENCE; CANCER PATIENT; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INDOLENT NONHODGKIN LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MEDICAL RECORD REVIEW; MIDDLE AGED; NONHODGKIN LYMPHOMA; PET-CT SCANNER; PRIORITY JOURNAL; RADIATION ATTENUATION; RETROSPECTIVE STUDY; BIOPSY; LYMPHOMA, NON-HODGKIN; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; BIOPSY; BONE MARROW; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84931576201     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12483     Document Type: Article

References (15)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignan M, Conti PS. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 2009;14(Suppl 2):30-40.
3. Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Nievelstein RA. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2014;41:565-74.
4. Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Littooij AS, Nievelstein RA. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol 2014;25:921-7.
5. Knopp MV, Bischoff H, Rimac A, Oberdorfer F, van Kaick G. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol 1996;23:845-9.
6. Salaun PY, Gastinne T, Bodet-Milin C, Campion L, Cambefort P, Moreau A, Le Gouill S, Berthou C, Moreau P, Kraeber-Bodere F. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 2009;36:1813-21.
7. Chiang SB, Rebenstock A, Guan L, Alavi A, Zhuang H. Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging. Clin Nucl Med 2003;28:674-6.
8. El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012;30:4508-14.
9. Cortes-Romera M, Sabate-Llobera A, Mercadal-Vilchez S, Climent-Esteller F, Serrano-Maestro A, Gamez-Cenzano C, Gonzalez-Barca E. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy. Clin Nucl Med 2014;39:e46-52.
10. Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, Carr R. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 2013;122:61-7.
11. Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, Dygai-Cochet I, Legouge C, Casasnovas O, Brunotte F. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 2013;54:1244-50.
12. Yao WJ, Hoh CK, Hawkins RA, Glaspy JA, Weil JA, Lee SJ, Maddahi J, Phelps ME. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med 1995;36:794-9.
13. Jacene HA, Ishimori T, Engles JM, Leboulleux S, Stearns V, Wahl RL. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med 2006;47:950-6.
14. Coller BS, Chabner BA, Gralnick HR. Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. Am J Hematol 1977;3:105-19.
15. Haddy TB, Parker RI, Magrath IT. Bone marrow involvement in young patients with non-Hodgkin's lymphoma: the importance of multiple bone marrow samples for accurate staging. Med Pediatr Oncol 1989;17:418-23.